Sebastian C. Tume

Sebastian C. Tume

Auto-generated profile, based on publicly available information

Sebastian C. Tume

Department of Pediatrics, Baylor College of Medicine, Division of Critical Care Medicine, Texas Children’s Hospital, Houston, TX

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2022 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
STSebastian C. Tume
Sebastian C. Tume
AFAndres A. Fuentes-Baldemar
Andres A. Fuentes-Baldemar
MAMarc Anders
Marc Anders
JSJoseph A. Spinner
Joseph A. Spinner
HTHari Tunuguntla
Hari Tunuguntla
IAIki Adachi
Iki Adachi

11 January 2021 in ASAIO Journal
Verified
Journal Article
Closed access
JSJoseph A. Spinner
Joseph A. Spinner
HTHari P. Tunuguntla
Hari P. Tunuguntla
STSebastian C. Tume
Sebastian C. Tume
BEBarbara A. Elias
Barbara A. Elias
JMJason Mcmullen
Jason Mcmullen
IAIki Adachi
Iki Adachi
The Jarvik 2015 Ventricular Assist Device (VAD) (Jarvik Inc, New York, NY) is the first and currently only continuous-flow VAD specifically designed for small children, and it is being evaluated in the so-called Pump for Kids, Infants, and Neonates (PumpKIN) trial. Due to the strict inclusion criteria of the trial, there have been a group of patients who failed to meet the criteria and therefore received the Jarvik 2015 VAD under the designation of “compassionate use.” This is the same phenomenon seen previously during the Berlin Heart EXCOR trial. While we await the results of the PumpKIN trial, which will report the device performance in a strictly selected population, the compassionate use cases represent actual “real world” experiences. We describe herein our experience of two compassionate use cases. In particular, this report has a special emphasis on the power consumption and hemolysis and inflammatory lab profile of the Jarvik 2015 VAD as hemocompatibility was the primary focus of the developmental and the preclinical phases.

12 December 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JMJiyong Moon
Jiyong Moon
HTHari Tunuguntla
Hari Tunuguntla
STSebastian Tume
Sebastian Tume
CBClaire Bocchini
Claire Bocchini
JCJunsang Cho
Junsang Cho
IAIki Adachi
Iki Adachi

5 February 2024 in ASAIO Journal
Verified
Journal Article
Closed access
SSSvetlana B. Shugh
Svetlana B. Shugh
STSebastian C. Tume
Sebastian C. Tume
NBNeha Bansal
Neha Bansal
JDJohn C. Dykes
John C. Dykes
JEJesse J. Esch
Jesse J. Esch
OIon behalf of ACTION Investigators
on behalf of ACTION Investigators
We report the largest pediatric multicenter experience with Impella pump use and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Utilizing the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) collaborative database, we conducted a retrospective, multicenter study of all patients with cardiogenic shock requiring VA-ECMO support with subsequent Impella implant between October 2014 and December 2021. The primary outcome was defined as death while on Impella support. Secondary outcomes were recovery, transplantation, and transition to durable ventricular assist device (VAD) at the time of Impella explantation. Adverse events were defined according to the ACTION registry criteria. Twenty subjects were supported with Impella; Impella 2.5 (n = 3), CP (n = 12), 5.0/5.5 (n = 5). The median Interquartile range (IQR) age, weight, and body surface area at implantation were 15.6 years (IQR = 13.9–17.2), 65.7 kg (IQR = 53.1–80.7), and 1.74 m2 (IQR = 1.58–1.98). Primary cardiac diagnoses were dilated cardiomyopathy/myocarditis in nine (45%), congenital heart disease in four (20%), graft failure/rejection in four (20%), and three (15%) others. Most common adverse events included hemolysis (50%) and bleeding (20%). There were two deaths (10%) in the cohort. Nine patients (45%) were explanted for recovery, eight (40%) were transitioned to a durable VAD, and one (5%) underwent heart transplantation. Impella percutaneous pump support should be considered in the older pediatric population supported with peripheral VA-ECMO, as a means of left heart decompression, and a strategy to come off ECMO to achieve endpoints of myocardial recovery, transition to a durable VAD, or transplantation.

10 June 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JEJonathan B. Edelson
Jonathan B. Edelson
SAShahnawaz Amdani
Shahnawaz Amdani
DRDavid N. Rosenthal
David N. Rosenthal
BKBenjamin Kroslowitz
Benjamin Kroslowitz
BMBrian Morray
Brian Morray
STSebastian Tume
Sebastian Tume

23 May 2022 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
KSKimberly E. Sawyer
Kimberly E. Sawyer
ACAlana T. Carpenter
Alana T. Carpenter
RCRyan D. Coleman
Ryan D. Coleman
STSebastian C. Tume
Sebastian C. Tume
Claire A CrawfordClaire A Crawford
Claire A Crawford
JCJessica A. Casas
Jessica A. Casas